62 research outputs found
Linear Predictive Spectral Analysis via the Lp Norm
This study involves linear predictive spectral analysis under the general LP norm; both one dimensional and two dimensional spectral estimation algorithms are developed. The objective in this study is determination of frequency resolution capability for various LP normed solutions to linear predictive spectral estimation equations. A modified residual steepest descent algorithm is utilized to generate the required solution. The research presented in this thesis could not have been accomplished without the support of the Oklahoma State University Research Consortium For Well Log Data Enhancement Via Signal Processing. The member companies of this consortium include Amococ Production Company, Area Oil and Gas Company, Cities Service Oil and Gas Corporation, Conoco, Exxon, IBM, Mobil Research and Development, Phillips Petroleum Corporation, Sohio Petroleum Company, and Texaco.Electrical Engineerin
Accelerated coronary vascular disease in the heart transplant patient: Coronary arteriographic findings
AbstractAnnual coronary arteriograms have been obtained from all heart transplant recipients at Stanford University Medical Center since 1969. Angiographic lesions in 81 transplant patients exhibiting coronary vascular disease were classified into three categories: type A, discrete or tubular stenoses; type B, diffuse concentric narrowing; and type C, narrowed irregular vessels with occluded branches. The 81 arteriograms showing transplant coronary vascular disease were contrasted with 32 from nontransplant patients with coronary artery disease analyzed in a similar fashion.The nontransplant angiograms showed 178 lesions, all of type A (discrete or tubular) morphology, 75% of which were located in primary epicardial coronary vessels and 25% in secondary branch vessels. In the patients with transplant coronary vascular disease, 349 (76%) of 461 lesions were type A: 57% in primary vessels, 42% in secondary branches and 1.4% in tertiary branches. Of the 112 type B and C lesions (diffuse narrowing, tapering and obliteration), 25% were in primary vessels, 44% in secondary vessels and 31% in tertiary branches (p < 0.05 for patients with transplant coronary vascular disease versus patients with nontransplant coronary artery disease). Total vessel occlusion was found in proximal or middle vessel segments in 96% and distally in 4% of patients with âordinaryâ coronary artery disease versus 49% distally in patients with transplant coronary disease (p < 0.002). In the presence of total vessel occlusion, collateral vessels were poor or absent in 92% of transplant versus 7% of nontransplant patients with coronary disease (p < 0.002).Therefore, coronary artery disease in transplant patients represents a mixture of typical atheromatous lesions and unique transplant-related progressive distal obliterative disease that occurs without collateral vessel development
Recommended from our members
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus
Chronic obstructive pulmonary disease (COPD) has been classically divided into blue bloaters and pink puffers. The utility of these clinical subtypes is unclear. However, the broader distinction between airway-predominant and emphysema-predominant COPD may be clinically relevant. The objective was to define clinical features of emphysema-predominant and non-emphysematous COPD patients. Current and former smokers from the Genetic Epidemiology of COPD Study (COPDGene) had chest computed tomography (CT) scans with quantitative image analysis. Emphysema-predominant COPD was defined by low attenuation area at -950 Hounsfield Units (LAA-950) â„10%. Non-emphysematous COPD was defined by airflow obstruction with minimal to no emphysema (LAA-950â<â5%). Out of 4197 COPD subjects, 1687 were classified as emphysema-predominant and 1817 as non-emphysematous; 693 had LAA-950 between 5â10% and were not categorized. Subjects with emphysema-predominant COPD were older (65.6 vs 60.6Â years, pâ<â0.0001) with more severe COPD based on airflow obstruction (FEV1 44.5 vs 68.4%, pâ<â0.0001), greater exercise limitation (6-minute walk distance 1138 vs 1331Â ft, pâ<â0.0001) and reduced quality of life (St. Georgeâs Respiratory Questionnaire score 43 vs 31, pâ<â0.0001). Self-reported diabetes was more frequent in non-emphysematous COPD (OR 2.13, pâ<â0.001), which was also confirmed using a strict definition of diabetes based on medication use. The association between diabetes and non-emphysematous COPD was replicated in the ECLIPSE study. Non-emphysematous COPD, defined by airflow obstruction with a paucity of emphysema on chest CT scan, is associated with an increased risk of diabetes. COPD patients without emphysema may warrant closer monitoring for diabetes, hypertension, and hyperlipidemia and vice versa. Trial registration: Clinicaltrials.gov identifiers: COPDGene NCT00608764, ECLIPSE NCT00292552
Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD
Implementing precision medicine for complex diseases such as chronic obstructive lung disease (COPD) will require extensive use of biomarkers and an in-depth understanding of how genetic, epigenetic, and environmental variations contribute to phenotypic diversity and disease progression. A meta-analysis from two large cohorts of current and former smokers with and without COPD [SPIROMICS (N = 750); COPDGene (N = 590)] was used to identify single nucleotide polymorphisms (SNPs) associated with measurement of 88 blood proteins (protein quantitative trait loci; pQTLs). PQTLs consistently replicated between the two cohorts. Features of pQTLs were compared to previously reported expression QTLs (eQTLs). Inference of causal relations of pQTL genotypes, biomarker measurements, and four clinical COPD phenotypes (airflow obstruction, emphysema, exacerbation history, and chronic bronchitis) were explored using conditional independence tests. We identified 527 highly significant (p 10% of measured variation in 13 protein biomarkers, with a single SNP (rs7041; p = 10â392) explaining 71%-75% of the measured variation in vitamin D binding protein (gene = GC). Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes. Most pQTLs were local (cis), but distant (trans) pQTL SNPs in the ABO blood group locus were the top pQTL SNPs for five proteins. The inclusion of pQTL SNPs improved the clinical predictive value for the established association of sRAGE and emphysema, and the explanation of variance (R2) for emphysema improved from 0.3 to 0.4 when the pQTL SNP was included in the model along with clinical covariates. Causal modeling provided insight into specific pQTL-disease relationships for airflow obstruction and emphysema. In conclusion, given the frequency of highly significant local pQTLs, the large amount of variance potentially explained by pQTL, and the differences observed between pQTLs and eQTLs SNPs, we recommend that protein biomarker-disease association studies take into account the potential effect of common local SNPs and that pQTLs be integrated along with eQTLs to uncover disease mechanisms. Large-scale blood biomarker studies would also benefit from close attention to the ABO blood group
The First Data Release of the Sloan Digital Sky Survey
The Sloan Digital Sky Survey has validated and made publicly available its
First Data Release. This consists of 2099 square degrees of five-band (u, g, r,
i, z) imaging data, 186,240 spectra of galaxies, quasars, stars and calibrating
blank sky patches selected over 1360 square degrees of this area, and tables of
measured parameters from these data. The imaging data go to a depth of r ~ 22.6
and are photometrically and astrometrically calibrated to 2% rms and 100
milli-arcsec rms per coordinate, respectively. The spectra cover the range
3800--9200 A, with a resolution of 1800--2100. Further characteristics of the
data are described, as are the data products themselves.Comment: Submitted to The Astronomical Journal. 16 pages. For associated
documentation, see http://www.sdss.org/dr
Non-Standard Errors
In statistics, samples are drawn from a population in a data-generating process (DGP). Standard errors measure the uncertainty in estimates of population parameters. In science, evidence is generated to test hypotheses in an evidence-generating process (EGP). We claim that EGP variation across researchers adds uncertainty: Non-standard errors (NSEs). We study NSEs by letting 164 teams test the same hypotheses on the same data. NSEs turn out to be sizable, but smaller for better reproducible or higher rated research. Adding peer-review stages reduces NSEs. We further find that this type of uncertainty is underestimated by participants
The clinical features of the overlap between COPD and asthma
<p>Abstract</p> <p>Background</p> <p>The coexistence of COPD and asthma is widely recognized but has not been well described. This study characterizes clinical features, spirometry, and chest CT scans of smoking subjects with both COPD and asthma.</p> <p>Methods</p> <p>We performed a cross-sectional study comparing subjects with COPD and asthma to subjects with COPD alone in the COPDGene Study.</p> <p>Results</p> <p>119 (13%) of 915 subjects with COPD reported a history of physician-diagnosed asthma. These subjects were younger (61.3 vs 64.7 years old, p = 0.0001) with lower lifetime smoking intensity (43.7 vs 55.1 pack years, p = 0.0001). More African-Americans reported a history of asthma (33.6% vs 15.6%, p < 0.0001). Subjects with COPD and asthma demonstrated worse disease-related quality of life, were more likely to have had a severe COPD exacerbation in the past year, and were more likely to experience frequent exacerbations (OR 3.55 [2.19, 5.75], p < 0.0001). Subjects with COPD and asthma demonstrated greater gas-trapping on chest CT. There were no differences in spirometry or CT measurements of emphysema or airway wall thickness.</p> <p>Conclusion</p> <p>Subjects with COPD and asthma represent a relevant clinical population, with worse health-related quality of life. They experience more frequent and severe respiratory exacerbations despite younger age and reduced lifetime smoking history.</p> <p>Trial registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00608764">NCT00608764</a></p
- âŠ